Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: DeCode Marks Q1 With Strong Revenue Growth, Narrowed Loss

NEW YORK, May 14 - DeCode said last night that an increase in corporate partnerships helped drive strong first-quarter revenue growth and a narrowed net loss.


Total revenue for the period ended March 31 was $9.5 million, an 88-percent increase from the $5.0 million it posted one year ago, the company said.


R&D spending for the quarter dipped to just under $18 million from more than $20 million in the first quarter 2002. This, plus 8.4 million new shares issued following DeCode's acquisition of MediChem Life Sciences in late March, helped narrow net loss to $11.2 million, or $.24 per share, from $16.1 million, or $.37 per share, in the year-ago period.


DeCode said it had slightly more than $147 million in cash and cash equivalents as of March 31.


Click here for more information.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.